MITSUBISHI TANABE PHARMA CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

Phase 3

Completed

Conditions: Immunization

Interventions: Biological: DPT-IPV-Hib (Combined Vaccine)

First Posted Date: 2017-06-15

Last Posted Date: 2025-01-03

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 33

Registration Number: NCT03188692

Locations: 🇯🇵
Investigational site 3, Tokyo, Japan
🇯🇵
Investigational site 1, Chiba, Japan
🇯🇵
Investigational site 2, Tokyo, Japan

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Phase 2

Completed

Conditions: Tardive Dyskinesia

Interventions: Drug: MT-5199
Drug: Placebo

First Posted Date: 2017-06-05

Last Posted Date: 2023-09-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 256

Registration Number: NCT03176771

Locations: 🇯🇵
Nanko Kokorono Clinic, Fukushima, Japan
🇯🇵
Takeda General Hospital, Fukushima, Japan
🇯🇵
Holy Cross Hospital, Gifu, Japan

and more 79 locations

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Painful Diabetic Peripheral Neuropathy

Interventions: Drug: MT-8554 middle dose
Drug: MT-8554 low dose
Drug: MT-8554 high dose
Drug: Placebo

First Posted Date: 2017-06-01

Last Posted Date: 2018-08-27

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 61

Registration Number: NCT03172598

Locations: 🇵🇱
Investigational center, City Name, Poland

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-2990
Drug: Placebo

First Posted Date: 2017-05-17

Last Posted Date: 2018-01-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 40

Registration Number: NCT03156738

Locations: 🇳🇱
Pharmaceutical Research Associates (PRA) Health Sciences, NZ Groningen, Netherlands

Phase 3 Study of BK1310 in Healthy Infants

Phase 3

Completed

Conditions: Immunization; Infection

Interventions: Biological: Hib vaccine
Biological: DPT-IPV-Hib-High（Combined Vaccine）
Biological: DPT-IPV-Hib-Low（Combined Vaccine）
Biological: DPT-IPV

First Posted Date: 2016-12-14

Last Posted Date: 2025-01-07

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 370

Registration Number: NCT02992925

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-4129
Drug: Placebo

First Posted Date: 2016-11-02

Last Posted Date: 2017-05-18

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 116

Registration Number: NCT02953132

Locations: 🇳🇱
Pharmaceutical Research Associates (PRA) Health Sciences, City Name, Netherlands

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Teneligliptin 20mg
Drug: Metformin ≥ 1000 mg

First Posted Date: 2016-10-05

Last Posted Date: 2022-03-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 247

Registration Number: NCT02924064

Locations: 🇨🇳
Investigational center, Beijing, China

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

Phase 2

Completed

Conditions: NASH

Interventions: Drug: MT-3995
Drug: Placebo

First Posted Date: 2016-10-04

Last Posted Date: 2019-09-06

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 48

Registration Number: NCT02923154

Locations: 🇯🇵
Investigational site, Osaka, Japan

Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Teneligliptin 20mg

First Posted Date: 2016-09-27

Last Posted Date: 2022-03-09

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 254

Registration Number: NCT02916706

Locations: 🇨🇳
Investigational center, Beijing, China

Mass Balance Study of MT-3995

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: MT-3995

First Posted Date: 2016-09-14

Last Posted Date: 2017-01-31

Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Target Recruit Count: 9

Registration Number: NCT02900235

Locations: 🇬🇧
Investigational center, City name, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy